ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

Core Insights - BeOne Medicines Ltd. announced full results from the Phase 3 HERIZON-GEA-01 trial for ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy and PD-1 inhibitor TEVIMBRA® (tislelizumab) for treating HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma [1] Group 1 - The trial evaluated the efficacy of ZIIHERA® as a first-line treatment option [1] - The study included data on the combination of ZIIHERA® with and without TEVIMBRA® [1] - The focus of the trial was on patients with HER2-positive gastroesophageal adenocarcinoma [1]